[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533347":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":18,"responsibleParty":37,"collaborators":7,"id":40,"slug":7,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":7,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":47,"minAge":48,"maxAge":7,"enrollmentInfo":49,"targetDuration":7,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Copenhagen University Hospital, Hvidovre","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Jonas A Baekdal, MD","University hospital, Hvidovre","PRINCIPAL_INVESTIGATOR",[14],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","+45 60134687","jonas.aggerholm.baekdal.02@regionh.dk",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Respiratory Research Unit Hvidovre Department of Respiratory Medicine, Copenhagen University Hospital","RECRUITING","Hvidovre","Capital Region","2650","Denmark","DK",{"type":28,"coordinates":29},"Point",[30,31],12.47708,55.64297,{"lat":31,"lon":30},[34],{"name":35,"role":15,"phone":36,"phoneExt":7,"email":17},"jonas A Baekdal, MD","+4523497817",{"type":12,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Jonas Baekdal","Medical doctor","100533347",false,"NCT06224634","The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance","The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance: a Longitudinal Cohort Study","Inclusion Criteria:\n\n* Patients planning to start treatment with anti-IL-17 antibodies\n\nExclusion Criteria:\n\n* Current pregnancy\n* FEV1 \\\u003C 1.5L or less than 60% of predicted value expected.\n* Previous anaphylactic shock or severe allergic reaction to medicine\n* Uncontrolled hypertension\n* Myocardial infarction or stroke within the last 3 months\n* Known aortic aneurysm\n* Recent eye surgery or risk of elevated intracranial pressure\n* Treatment with systemic corticosteroids within 6 weeks",true,"ALL","18 Years",{"count":50,"type":51},74,"ESTIMATED","OBSERVATIONAL","This observational longitudinal cohort study aims to assess the effect of monoclonal antibodies targeting interleukin 17 (anti-IL-17) on airway hyperreactivity and airway resistance. The study involves adult participants suffering from dermatological or rheumatological illness, who are planning to start treatment with monoclonal antibodies targeting interleukin 17 as a part of the treatment of these diseases.\n\nThe primary outcome of this study will be changes in airway hyperresponsiveness to methacholine challenge reported as response-dose-ratio before and after initiation of anti-IL17 treatment regardless of presence of respiratory disease. Furthermore, the potential effect of anti-IL-17 on airway resistance will be assessed using conventional spirometry for measuring changes in FEV1 and Airwave oscillometry.\n\nA reduced degree of airway hyperreactivity and airway resistance after initiating ani-IL-17 could indicate effectiveness of anti-IL-17 in asthma patients which would have to be examined further in a population of asthma patients.",[55],"Asthma",[55,57,58,59,60],"Interleukin 17","ankylosing spondylitis","Psoriasis","Airway hyperresponsiveness","2025-03-14",{"date":63,"type":64},"2025-03-18","ACTUAL",{"date":66,"type":64},"2024-08-02",{"date":68,"type":51},"2027-01",{"name":5,"class":6},1]